Name: Walgreens Boots Alliance Inc. (NASDAQ:WBA) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Revenues as Reported

Revenues as Reported

Download chart

Walgreens Boots Alliance Inc., income statement, revenues

US$ in millions

12 months ended:	Aug 31, 2019	Aug 31, 2018	Aug 31, 2017	Aug 31, 2016	Aug 31, 2015	Aug 31, 2014
Pharmacy	77,192)	71,055)	60,607)	—)	—)	—)
Retail	27,340)	27,337)	26,695)	—)	—)	—)
Retail Pharmacy USA	104,532)	98,392)	87,302)	—)	—)	—)
Pharmacy	4,080)	4,360)	4,180)	—)	—)	—)
Retail	7,382)	7,921)	7,633)	—)	—)	—)
Retail Pharmacy International	11,462)	12,281)	11,813)	—)	—)	—)
Pharmaceutical Wholesale	23,053)	23,006)	21,188)	—)	—)	—)
Eliminations	(2,181)	(2,142)	(2,089)	—)	—)	—)
Sales	136,866)	131,537)	118,214)	—)	—)	—)

Based on: 10-K (reporting date: 2019-08-31), 10-K (reporting date: 2018-08-31), 10-K (reporting date: 2017-08-31), 10-K (reporting date: 2016-08-31), 10-K (reporting date: 2015-08-31), 10-K (reporting date: 2014-08-31).

Total sales exhibited a consistent upward trajectory between 2017 and 2019, increasing from 118,214 million USD to 136,866 million USD. This growth was primarily underpinned by strong performance within the domestic market, which offset stagnation and declines observed in international operations.

Retail Pharmacy USA: The US segment demonstrated significant expansion, with total revenues rising from 87,302 million USD in 2017 to 104,532 million USD in 2019. This growth was driven predominantly by pharmacy sales, which increased from 60,607 million USD to 77,192 million USD. Conversely, retail sales remained largely stagnant, showing minimal movement from 26,695 million USD in 2017 to 27,340 million USD in 2019.
Retail Pharmacy International: International revenues showed volatility, peaking in 2018 at 12,281 million USD before declining to 11,462 million USD in 2019. Both pharmacy and retail components of this segment experienced contractions in the final year, with retail falling to 7,382 million USD and pharmacy decreasing to 4,080 million USD.
Pharmaceutical Wholesale: The wholesale division maintained a steady growth pattern, increasing from 21,188 million USD in 2017 to 23,053 million USD in 2019. A more pronounced increase occurred between 2017 and 2018, followed by relative stagnation in 2019.
Consolidated Revenue Impact: Total sales growth reflects the aggregation of these business segments net of intersegment eliminations, which grew slightly from -2,089 million USD to -2,181 million USD. The overall revenue expansion is heavily concentrated in the US pharmacy business, which constitutes the largest portion of the total revenue stream.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?